Best Direct Primary Care GLP-1 Providers in 2026 — Ranked & Reviewed
Insurance billing comes out of the model entirely in Direct Primary Care (DPC), replaced by a flat monthly fee paid to the practice. A small and growing set of DPC practices now put GLP-1 weight-loss medication inside that membership at wholesale or close to it. Set that against the direct-to-consumer marketplace pattern, where the medication alone runs $300-$500/month and no continuing primary-care relationship comes with it. Lab monitoring, dose adjustments and side-effect management all sit inside one ongoing provider relationship here, which most clinicians treat as the standard to aim for in chronic weight management. Expect a membership fee of $50-$150/month, with wholesale GLP-1 on top at $65-$300/month depending on the drug, the dose and the form. Where insurance will not cover brand-name Wegovy or Zepbound, this can be the cheapest total path to a GLP-1 plus comprehensive care.
1 provider compared
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
1 direct primary care glp-1 providers compared · independently scored against our six-factor methodology.
Rankings updated August 2026
Quick Picks: Top 1
| # | Provider | Score | |
|---|---|---|---|
| 1 | Primary Clinic (Direct GLP) | Visit |
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
Detailed Reviews
Primary Clinic (Direct GLP)
Best for: seeing what it charges before you answer any medical questions
What is sold here is Direct Primary Care membership, not a GLP-1 package. $89/mo covers primary care without limit, texting the clinic directly, virtual visits the same day and routine labs. Members then purchase compounded 503A GLP-1s at wholesale, no markup applied: $65/mo and up for semaglutide, $110/mo and up for tirzepatide. It runs in 10 states so far, and monitoring of the medication happens inside a continuing care relationship.
Score Breakdown
Pros
- ✓Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- ✓No FDA warning letter matched this operator when we searched our enforcement register
Cons
- ✗Coverage is published for 10 states only, so this may not reach you
- ✗No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
How we rank, and what counts as “legit”
Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.
Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].
How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].
Frequently Asked Questions
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.